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Background: Endoscopic treatment of early neoplastic lesions in oesophagus has evolved as a valid and less
invasive alternative to surgical resection. These endoscopic interventions are minimal invasive treatment options
usually done with sedation on an outpatient basis. The aim of this trial is to determine the safety and effectiveness
of dexmedetomidine sedation compared to the standard used propofol TCI sedation during endoscopic
oesophageal interventions.
Methods: The study will be performed as a randomized controlled trial. The first 64 consenting patients will be
randomized to either the propofol or the dexmedetomidine group. Following endoscopy patients and
gastroenterologists have to fill in questionnaires (PSSI, CSSI) (see abbreviations) about their sedation experiences.
Additionally, patients have to accomplish the Trieger test before and after the procedure. Patient monitoring
includes time adapted HR, SO2, ECG, NIBP, exCO2, NICO, sweat conductance measurement, OAA/S, and the Aldrete
score. Effectiveness of sedation, classified by satisfaction levels and pain and sedation score measured by
questionnaires is the primary outcome parameter. Respiratory and hemodynamic complications are surrogate
parameters for the secondary outcome parameter “safety”.
Discussion: The acceptance level among patients after propofol sedation is high. Dexmedetomidine is a relatively
new representative for procedural sedation. Has this new form of conscious sedation the potential to be safer and
more effective for patients and endoscopists than propofol during endoscopic oesophageal interventions?
Trial registration: This trial is registered in the ISRCTN Register (ISRCTN 68599804). It will be conducted in
accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical
research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The Departments of
Anesthesiology and Gastroenterology & Hepatology of the Academic Medical Center of Amsterdam are responsible
for the design and conduct of the trial.
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Early neoplasias in Barrett’s oesophagus bear the risk of
developing carcinoma (5.1–7 per 1000 person-years)
[1-3]. The last two decades, endoscopic treatment has
evolved as a valid and less invasive alternative to surgical
resection in patients with a low risk of lymph node me-
tastasis [4,5].* Correspondence: S.Eberl@amc.uva.nl
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reproduction in any medium, provided the orThe cornerstone of endoscopic therapy is endoscopic re-
section (ER), allowing curative removal and histological
staging of neoplasia. To prevent recurrences it is import-
ant to eradicate all intestinal metaplasia. One approach is
radiofrequency ablation (RFA) [6].
However, these procedures are long lasting, uncomfort-
able and stressful for most patients. Furthermore, they re-
quire patients being sedated, but easily arousable in order
to provide excellent view to the oesophagus. Conscious
sedation is a strategy for improving patient safety and
comfort during these procedures. In particular, propofol isd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and termination of action [7]. However, the most import-
ant disadvantage of propofol is the risk of a rapid change
from conscious to deep sedation or even general anesthesia
with consecutive cardiopulmonary depression [8]. There-
fore, other pharmacological agents that induce an adequate
level of sedation without respiratory depression are of
increasing interest to clinicians. Dexmedetomidine, a
short-acting selective alpha2-agonist, possesses anxio-
lytic, hypnotic, and analgesic properties [9]. Patients
receiving dexmedetomidine are easily arousable, yet ap-
pear calm and comfortable. When they remain unstimu-
lated, patients return to a hypnotic state. Furthermore,
dexmedetomidine provides hemodynamic stability and ap-
pears to have no clinically important adverse effects on
respiration [10].
The aim of this trial is to determine the safety and ef-
fectiveness of dexmedetomidine compared to the in our
hospital standard used propofol sedation, both adminis-
tered by anesthesia nurses.
Methods/Design
Trial design
The study is designed as a prospective randomized con-
trolled trial.
Participants
The study takes place at the Department of Gastroenter-
ology and Hepatology in the Academic Medical Center
(AMC) of the University of Amsterdam beginning July
2012 to Augustus 2013. Eligible patients for participation
in this clinical trial are those planned to undergo elective
endoscopic oesophageal interventions (mapping, ER, or
RFA), aged above 18 years, and ASA classification I-III,
who give written informed consent.
Exclusion criteria
 Age range < 18 years
 ASA classification IV and V
 Allergic reaction to planned medication in the
patients’ medical history
 Unregulated hypertension
 Hypovolemia or hypotension (systolic blood
pressure <80 or mean arterial pressure <50 mmHg)
 Severe bradycardia (heart rate < 50/min) and / or
related brady-dysrhythmias (e.g. advanced heart
block)
 Impaired ventricular function (left ventricular
ejection fraction <30%)
 Impaired renal function, GFR less than 15ml/min or
undergoing hemodialysis
 Impaired liver function
 Substance abuseThe number of excluded patients and the reasons for
their exclusion will be recorded and also reported in the
manuscript according to the CONSORT statement.
Informed consent
Patients scheduled for an elective endoscopic oesophageal
intervention (mapping, ER, or RFA) will be asked – after
checking inclusion and exclusion criteria - by phone to
participate. The exclusion criteria will be checked once
again during this conversation and if they are eligible for
inclusion and interested in participating in our study, the
patient information will be sent. Patients are included after
written informed consent. Patients are free to participate
in this study. If they deny taking part they will get the
standard sedation with propofol and alfentanil provided by
an anesthesia nurse as usual in daily practice for endo-
scopic oesophageal interventions. Patients don’t have to
answer questionnaires, however - reflecting common
monitoring practice - SO2, ECG, NIBP and exCO2 will be
monitored in the same way.
Randomization
In the AMC, endoscopic oesophageal interventions are
routine procedures performed on Monday and Friday on
one intervention suite at the Department of Gastroenter-
ology & Hepatology. Following informed consent, pa-
tients are computer generated randomized 1:1 to either:
propofol TCI (group 1, n = 32) or dexmedetomidine
(group 2, n = 32) (Figure 1).
Patients are blinded to the sedation regimen they are
supposed to get.
Sedation within both groups is performed by a special
anesthesia nurse who will not be blinded to the used form
of sedation. The other attending parties (endoscopist, endo-
scopic nurse) are blinded.
All interventions are performed by one of two experi-
enced endoscopists.
Intervention
After randomization patients are allocated to group 1 or 2,
and prepared for endoscopy. An intravenous line is
inserted, and 500 ml NaCl 0,9%, glycopyrrolate 0.2 mg
and lidocaine 50 mg are administered. Five minutes before
insertion of the endoscope, the pharynx is sprayed with
10% xylocaine spray (xylocaine 10%, Astra). 2 L/min of
oxygen will be administered by a nasal mask from start of
sedation till the end of the endoscopic procedure.
Group 1 will receive sedation using a propofol Target
Controlled Infusion (TCI) system. This TCI system is
weight and age adapted pre-programmed using the Marsh
pharmacokinetic model to attain a user defined propofol
blood target level.




Telephone call 24 hours later:
Post procedural questionnaire (part2): PSSI, CSSI (patient, GE)






Pre procedural questionnaire (patient, GE)
Trieger test (patient)
Monitoring: SO2, exCO2, ECG, NIPD, NICO, sweat conductance
Recovery
Monitoring: SO2, ECG, NIPD
Aldrete score: 0, 30, 60 min
Trieger test: 30 min
Post procedural questionnaire (part1): PSSI, CSSI (patient, GE)
Figure 1 Consort flow diagram.
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will be started with a loading dose of 1 μg/kg intravenously
over 10 min. After this loading bolus, procedure is started
and dexmedetomidine continued throughout the procedure
within the range of 0.7 -1 μg/kg/h titrated to a targeted level
of sedation [10]. Among patients older than 65 years loading
dose will be reduced to 0.5 μg/kg. continued throughout the
procedure within the range of 0.7 -1 μg/kg/h titrated to a
targeted level of sedation [10]. Among patients older than
65 years loading dose will be reduced to 0.5 μg/kg.
Both forms of sedation are supplied by an anaesthesia
nurse to achieve the targeted sedation score (Observer’s
Assessment of Alertness/Sedation OAAS Scale ≤ 4), which
means the patients maximal lethargic response to their
name spoken in normal tone.
If OAA/S > 4, which means that the patient is too alert
or agitated to tolerate the procedure, additional sedation
will be provided with step up of the TCI (group 1) or an
additional doses of propofol 20 mg (group 2).
Drug infusion will be discontinued if any of the follow-
ing adverse events are observed: recurrent apnea (respira-
tory rate <6/min) lasting more than 60 seconds over a 5
min observation period, sustained episodes (60 seconds)
SO2 < 90% over a 5 min observation period, decrease of
heart rate to < 50 beats/min, mean non-invasive blood
pressure < 70% of the initial measurement.Monitoring
Reflecting common practice, patients are constantly
monitored during endoscopy with HR, SO2, ECG, NIBP,
and exCO2 measured at 5-minute intervals. Additionally
sweat production as a sign of stress will be recorded with
a wearable ambulatory skin conductance measurement
and recording tool suitable for monitoring hot flashes.
Furthermore, non invasive cardiac output (NICO) is mea-
sured using a Nexfin monitor.
We will record total procedure time, all drugs, drug
amounts and time of administration, time from the end of
the procedure until Observer’s Assessment of Alertness/
Sedation (OAA/S) score ≥ 4, any respiratory and cardio-
vascular problems and all actions visibly taken to prevent
or treat these problems, such as chin lift/jaw thrust, stimu-
lating the patient, temporary mask ventilation, etc. The
following were considered as significant events: a decline
in SpO2 to less than 90%, breathing frequency less than 6
breath/min, or an increase of etCO2 > 50 mmHg; a change
in heart rate to less or more than 20% of baseline or oc-
currence of any arrhythmia’s; blood pressure less or more
than 20% of the first blood pressure determined.
At arrival in the recovery room patients will be moni-
tored by pulse oximetry (SO2), ECG and NIBP only.
The level of recovery from anesthesia and the return of
psychomotor fitness will be assessed using the modified
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rival in the recovery room, 30 and 60 min later. All pa-
tients will stay in the recovery room for at least two hours.
Ready for virtual discharge will be declared when an
Aldrete Score ≥ 9 or pre-procedure score is met.
“Discharge criteria” require further that the patient is
awake and alert with stable vital signs, is able to ambu-
late without assistance, and is free of side effects of the
drugs employed during the procedure.
Pain evaluation
To classify the pain score the Society of Critical Care
Medicine recommends self-reporting by conscious se-
dated patients using the numerical rating scale (NRS,
range 0–10) [11]. So we decided to use the NRS to esti-
mate patients’ pain. However, we had to recognize, that
the use of a self reporting score -even in only conscious
sedated patients- is sometimes complicated and unreli-
able because of lack of comprehension and communica-
tion tools. Therefore, we decided to use a modified
version of the Behavioural Pain Scale for not-intubated
patients (BPS-NI) [12] as an additional rating method to
assess the pain level among patients with altered level of
consciousness. The BPS – IN evaluates three behavioural
domains (i.e., facial expression, movements of upper
limbs and vocalization). Each domain contains four de-
scriptors which are rated on a 1–4 scale, and the total
BPS value ranges from 3 (no pain) to 12 (most pain).
Patients with a NRS > 4 or BPS-NI ≥ 7 will be given an
dose of 100 μg alfentanil.
The amount of alfentanil and propofol used as an ad-




Patients have to accomplish the Trieger test (before and
30 minutes after the procedure) as a means of psycho-
motoric recovery [13]. For the Trieger test, patients have
to connect points forming a figure with a line using a
pen. Missing points as well as the distances of the line
from the true points are noted and rated as score post/
preprocedural.
Questionnaires
Before procedure patients and GE’s have to fill in a ques-
tionnaire concerning basic information and specific ex-
pectations of the procedure.
Following the procedure and before discharge, patients
and gastroenterologist are urged to fill in questionnaires
modified from the Patient Satisfaction with Sedation Instru-
ment (PSSI), respectively Clinical Satisfaction with Sedation
Instrument (CSSI), which provide feasible, reliable, and
valid assessment of procedural sedation satisfaction foroutpatients [14]. Vargo et al. [14] developed this score
system with finally 4 subscores to describe patients and
3 subscores to describe endoscopists’ satisfaction. Sub-
scores for the PSSI contain questions about sedation deliv-
ery, procedural recall, sedation side effects, and global
satisfaction. Subscores for the CSSI refer to corresponding
issues among gastroenterologists: Sedation administration,
recovery/ post-op and global satisfaction.
Patients and endoscopists could classify their satisfac-
tion or dissatisfaction during the procedure on a ques-
tionnaire ranging from 1 = very satisfied to 7 = very
dissatisfied.
A follow-up telephone call will be made 24 h later ask-
ing questions from part two of the PSSI questionnaire
concerning global satisfaction. Patients will also be asked
about their willingness to undergo the same procedure
with the same sedation regimen in the future if required.
Objectives
Primary objective
The primary aim of this prospective randomized con-
trolled study is to determine, whether dexmedetomidine is
more effective for sedation during endoscopic oesophageal
interventions than our in house standard regime with pro-
pofol TCI. Surrogate marker of effectiveness are satisfac-
tion levels, pain score, and sedation score measured by
questionnaires which have to be completed by both, pa-
tient and GE, and patients sweat production as a sign of
stress response.
Secondary objective
As a secondary objective we set out to clarify, whether
dexmedetomidine sedation is safer for the patient with
regard to respiratory and cardiovascular side effects than
sedation with propofol TCI. Surrogate parameters of
pulmonary and cardiovascular events are a decline in
oxygen saturation (SO2) to less than 90%, a rise in
exCO2 > 50 mmHg, or a respiratory rate < 6/min; heart
rate less or more than 20% of the baseline rate or occur-
rence of an arrhythmia; blood pressure less or more than
20% of the first pressure measured.
Sample size
Regarding the primary outcome parameter effectiveness
and satisfaction, our trial is set up as a study of a con-
tinuous response variable from two independent sub-
jects. Sample size calculation is based on a former study
(PAGE- study, ISRCTN 83950185). This study shows
significant and thus important differences between the
study-groups within the validated patient and gastroen-
terologists questionnaires. Within these questionnaires
the maximum number of points patients or endoscopists
can award, is seven reaching from 1 (highly satisfied) to
7 (very dissatisfied). With a true difference between two
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necessary to demonstrate a statistical significance for glo-
bal satisfaction (patient and gastroenterologist) at an α of
0.05 and a 1-β of 0.8. If the calculated drop out is 20%, the
estimated sample size will be 32 patients per group.
Statistical analysis
Statistical analyses will be performed using PASW statis-
tics (version 18.0).
All data will be checked for normal distribution using
the Kolmogorov-Smirnonov test. The two groups will be
compared using a Student t test or multifactorial ANOVA
(Kruska Wallis) with a step-down post hoc adjustment, or
a Mann–Whitney U-test (for differences between two
groups), where appropriate. Data are presented as mean ±
SD or median/25/75 percentile.
Ethical approval
Ethical approval was obtained from the Medical Ethics
Committee of the Academic Medical Center, Amsterdam,
the Netherland (NL). A marginal review was performed by
the National Authority, the Central Committee on Re-
search Involving Human Subjects (CCMO), and there were
no objections to perform this study (NL36861.018.11).
Discussion
Mapping, ER, and RFA are nowadays widespread used
as a treatment for early neoplastic oesophageal or gastric
lesions. However, it is still a matter of discussion which
form of sedation is necessary and safe: conscious or deep
sedation.
Propofol TCI combined is a tool for deep sedation,
with high levels of acceptance and satisfaction among
patients and gastroenterologist, but at a great risk of car-
diopulmonary depression. This is the reason why its ap-
plication in many countries is still limited to anesthesia
providers. Dexmedetomidine is a highly selective alpha2
agonist that provides anxiolyse and cooperative sedation
without respiratory depression. Hashiguchi [15] performed
a study (n = 40) to investigate the safety and efficacy of
dexmedetomidine for sedation of patients undergoing rou-
tine upper gastrointestinal endoscopy. The results of this
randomized study demonstrate that dexmedetomidine
was as safe and effective as midazolam for producing and
maintaining adequate short-term sedation in patients
undergoing upper GI endoscopy. Unfortunately, length
and sort of upper GI were not described.
Takimoto [16] compared dexmedetomidine with pro-
pofol and midazolam for sedation of 90 patients during
endoscopic submucosal dissection of gastric cancer and
found dexmedetomidine safe and effective. However, in
this study only HR, NIBD, ECG and SO2 were moni-
tored in intervals of 10 min and patient and endoscopist
satisfaction was not mentioned.Mazanikov et al. [17] used dexmedetomidine for sed-
ation of patients with chronic alcohol abuse during
ERCP and found an insufficient sedative effect.
This RCT is the first one with a broad hemodynamic
monitoring including exCO2, NICO and sweat conduct-
ance/stress monitoring and validated questionnaires on
patient and endoscopists satisfaction. So, this study will
provide detailed information about the effect of dexme-
detomidine concerning procedural sedation aspects, side
effects, adverse events, procedural time and recovery
time.
We expect that dexmedetomidine is a safe and effect-
ive possibility to run through oesophageal endoscopic
procedure with satisfied patients and endoscopists.
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